These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 10932224

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
    Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D.
    Cancer Res; 2000 Nov 15; 60(22):6359-66. PubMed ID: 11103798
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
    Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng X.
    Ai Zheng; 2004 Dec 15; 23(12):1666-70. PubMed ID: 15601557
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C, Lemmon M, Kirn D.
    Clin Cancer Res; 2000 Dec 15; 6(12):4908-14. PubMed ID: 11156251
    [Abstract] [Full Text] [Related]

  • 8. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
    Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D.
    Gene Ther; 2001 May 15; 8(10):746-59. PubMed ID: 11420638
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL.
    J Clin Oncol; 2004 Aug 01; 22(15):3061-9. PubMed ID: 15284256
    [Abstract] [Full Text] [Related]

  • 10. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA.
    J Clin Oncol; 2004 Jan 15; 22(2):262-8. PubMed ID: 14722034
    [Abstract] [Full Text] [Related]

  • 11. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R.
    Anticancer Res; 2006 Jan 15; 26(1B):585-90. PubMed ID: 16739325
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2005 May 20; 23(15):3562-7. PubMed ID: 15908667
    [Abstract] [Full Text] [Related]

  • 15. Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck.
    Tulunay OE, Enamorado II, Kucuk O, Heilbrun LK, Otero JE, Korkmaz H, Blumberg R, Jacobs JR.
    Head Neck; 2007 Mar 20; 29(3):267-71. PubMed ID: 17163471
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD, Meyerson MB, Neal CR, Hamann MS, Bost AL, Anagnost JW, Ungaro PC, Pollock HD, McMurray JE, Wilson EP, Kotwall CA.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):698-704. PubMed ID: 14967423
    [Abstract] [Full Text] [Related]

  • 18. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW, Li D, McQuone SJ, Ralston R.
    Laryngoscope; 2005 Mar 01; 115(3):391-404. PubMed ID: 15744147
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
    Benasso M, Ponzanelli A, Merlano M, Numico G, Ricci I, Vigo V, Grossi F, Amadori D, Cavallo G, Capaccetti B, Taveggia P, Boni L, Rosso R.
    Acta Oncol; 2006 Mar 01; 45(2):168-74. PubMed ID: 16546862
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.